Cellulose-based amorphous solid dispersions enhance rifapentine delivery characteristics in vitro

Controlling Particle Size and Release Kinetics in the Sustained Delivery of Oral Antibiotics Using pH-Independent Mucoadhesive Polymers

“…For instance, clarithromycin has been protected with carboxyl-containing cellulose derivatives forming nanoparticles to quench the acid-catalyzed degradation in the stomach and improve the aminomacrolide antibiotic solubility in the intestine 7 . Likewise, cellulose derivatives have also been used to protect rifapentine from gastric degradation and to improve its reduced solubility at intestinal pH 8 . According to Singh et al, 26.5% of free Rif was degraded using simulated gastric fluid being its degradation aggravated under the presence of one of the secondary antibiotics used (isoniazid) as common combination therapy 9 .…”

Amorphisation of Free Acid Ibuprofen and Other Profens in Mixtures with Nanocellulose: Dry Powder Formulation Strategy for Enhanced Solubility

“…Cellulose esters and, in particular, alkyl cellulose ω-carboesthers with hydrophobic side chains of various lengths have been explored for their amorphization potential of poorly soluble drugs [40,41]. For example, the amorphization of several poorly soluble anti-infective drugs such as rifapentine [42], ciprofloxacin [43], and ritonavir [44] was studied.…”

Amorphous drug substances

“…Druga generacja to amorficzne stałe rozproszenia (ASD), w których substancja lecznicza jest molekularnie rozproszona w matrycy amorficznego nośnika, zazwyczaj syntetycznego polimeru takiego jak poliwinylopirolidon (PVP), glikol polietylenowy (PEG) lub pochodne celulozy, tj. hydroksypropylometyloceluloza, octanobursztynian lub octan celulozy [11]. W zależności od wzajemnego oddziaływania substancji leczniczej z nośnikiem, wyróżnia się układy jednofazowe, czyli stałe roztwory i szkliste roztwory, oraz dwufazowemieszaniny eutektyczne i szkliste zawiesiny [12].…”